These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36094949)

  • 1. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.
    Hendryx M; Dong Y; Ndeke JM; Luo J
    PLoS One; 2022; 17(9):e0274519. PubMed ID: 36094949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.
    Luo J; Hendryx M; Dong Y
    Br J Cancer; 2023 Apr; 128(8):1541-1547. PubMed ID: 36765176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Fralick M; Chen SK; Patorno E; Kim SC
    Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
    Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
    Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk.
    Hu WS; Lin CL
    J Diabetes Complications; 2023 May; 37(5):108468. PubMed ID: 37043985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.
    Shen Y; Zhou J; Shi L; Nauman E; Katzmarzyk PT; Price-Haywood EG; Horswell R; Chu S; Yang S; Bazzano AN; Nigam S; Hu G
    Diabetes Obes Metab; 2020 Jul; 22(7):1197-1206. PubMed ID: 32166884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.
    Iskander C; Cherney DZ; Clemens KK; Dixon SN; Harel Z; Jeyakumar N; McArthur E; Muanda FT; Parikh CR; Paterson JM; Tangri N; Udell JA; Wald R; Garg AX
    CMAJ; 2020 Apr; 192(14):E351-E360. PubMed ID: 32392523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.
    Siao WZ; Lin TK; Huang JY; Tsai CF; Jong GP
    Diab Vasc Dis Res; 2022; 19(3):14791641221098168. PubMed ID: 35549730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2020 Dec; 19(1):206. PubMed ID: 33287812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Han SJ; Ha KH; Lee N; Kim DJ
    Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.